The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02028507
Recruitment Status : Completed
First Posted : January 7, 2014
Last Update Posted : January 20, 2021
Sponsor:
Collaborators:
Pfizer
AstraZeneca
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : January 14, 2019
Actual Study Completion Date : January 11, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 February 2, 2022
(Canceled on February 3, 2022)
February 3, 2022
 April 8, 2022
2 May 11, 2022
 February 8, 2023
3 February 10, 2023
(Canceled on March 2, 2023)
March 2, 2023
(Canceled on March 3, 2023)
March 3, 2023
 December 7, 2023
4 December 12, 2023
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):